Reference

Experimental antitumor agents from Solanum indicum L

Experimental antitumor agents from Solanum indicum L. Chiang, Hsuch Ching; Tseng, Tsui Hwa; Wang, Chau Jong; Chen, Chia Fu; Kan, Wei Song (Coll. Med., Natl. Taiwan Univ., Taipei, Taiwan). Anticancer Res., 11(5), 1911-17 (English) 1991. CODEN: ANTRD4. ISSN: 0250-7005. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 11 b-Sitosterol (SI-0), b-sitosterol glucoside (SI-1), dioscin (SI-2), Me protoprosapogenin A of dioscin (SI-3), Me protodioscin (SI-4) and protodioscin (SI-5) were isolated and characterized from the whole plant of Solanum indicum L. (Solanaceae). Except for b-sitosterol, these compds. have not been previously isolated from Solanum indicum L. 55056-80-9 and 54522-52-0 are cas registry numbers of chemicals which are used as reagents here. Both CHCl3 sol. (SI-IV) and insol. (SI-V) fractions of the ethanolic ext. (SI-I) showed cytotoxicity on seven cancer cell lines: Colo-205 (colon), KB (nasopharynx), HeLa (uterine cervix), HA22T (hepatoma), Hep-2 (laryngeal epidermoid), GBM8401/TSGH (glioma) and H1477 (melanoma). The purified constituents, SI-2 and SI-4 showed more potent effects by DEA and MTT assay. SI-2,3,4 and 5 also demonstrated cytotoxicity on cultured C6 glioma cells by PRE assay, SI-3,4 and 5 showed a tumor inhibitory effect in vivo in C6 glioma cells. In addn., SI-2 had an inhibitory effect on the DNA synthesis of C6 glioma cells at 10 mg/mL. .

Core 2 GlcNAc-transferase inhibitors III

All Rights Reserved. Core 2 GlcNAc-transferase inhibitors III. Chibber, Rakesh (Btg International Limited, UK). U.S.Chemicals with cas numbers 84633-36-3 and 55056-80-9 also play role. Pat. Appl. Publ. US 2007010462 A1 11 Jan 2007, 22pp. (English). (United States of America). CODEN: USXXCO. INCL: 514026000. APPLICATION: US 2006-481256 6 Jul 2006. PRIORITY: GB 2005-13881 6 Jul 2005. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The present invention relates to the use of known and novel compds. as pharmaceutical actives against diseases susceptible to treatment by modulation, eg. inhibition, of the enzyme Core 2 GlcNAc-transferase (EC 2.4.1.102), also known as b-1,6-N-acetylglucosaminyl transferase. The present application discloses further steroidal glycoside compds. that are inhibitors of core 2 GlcNAc-transferase and addnl. conditions in which these compds. have a therapeutic use. Examples of such conditions are inflammatory diseases such as atherosclerosis and multiple sclerosis, diabetes, cancer and its metastasis. .